ANTI-PD-1/TIM-3 BISPECIFIC ANTIBODY RO7121661

Metastatic Melanoma

Hoffmann-La Rochemonoclonal_antibodyPhase 1Dormant

CC

42/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 32/ 100
Competitive Position: 73/ 100

Competitive context

104 Active assets in the Metastatic Melanoma cohort.

Asset / Sponsor	Phase	Rating
Cediranib M.D. Anderson Cancer Center	Phase 2	BBB
DACARBAZINE Shanghai Junshi Bioscience Co., Ltd.	Phase 4	BBB
Ifa Craig L Slingluff, Jr	Phase 2	BB
Nivolumab Bristol-Myers Squibb	Phase 4	BB
Montanide Isa 51 Ludwig Institute for Cancer Research	Phase 2	BB

View all 50 →

Same molecule, other indications

ANTI-PD-1/TIM-3 BISPECIFIC ANTIBODY RO7121661 is also rated in:

esophageal squamous cell carcinomaDormant

CC

Indicative ·

47 / 100

small cell lung carcinomaDormant

CC

Indicative ·

44 / 100

non-small cell lung carcinomaDormant

CC

Indicative ·

42 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.